EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phage endolysins as new therapeutic options for multidrug resistant Staphylococcus aureus: an emerging antibiotic-free way to combat drug resistant infections

Melaku Ashagrie Belete, Selamyhun Tadesse, Mihret Tilahun, Ermiyas Alemayehu, Muthupandian Saravanan

Frontiers in Cellular and Infection Microbiology · 17.06.2024 · 14

DOI: 10.3389/fcimb.2024.1397935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 17.06.2024. Verfasst von Melaku Ashagrie Belete und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Science, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia. Hauptthemen laut MEDLINE: Drug Resistance, Multiple, Bacterial, Endopeptidases, Staphylococcal Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

phage endolysins, new therapeutic options, multidrug resistant Staphylococcus aureus, MDR -S.aureus, combating AMR Staphylococcus aureus (S. aureus) has developed various drug resistance mechanisms, which make it difficult to treat with conventional antibiotics.The most common drug resistance mechanisms of S. aureus include: productions of beta-lactamase, an enzyme that breaks down beta-lactam antibiotics such as penicillins and cephalosporins; methicillin resistance [methicillin-resistant S. aureus (MRSA)], a genetic mutation that allows them to produce an altered penicillin-binding protein (PBP2a), which has a reduced affinity for methicillin and other beta-lactam antibiotics; vancomycin resistance [vancomycin-resistant S. aureus (VRSA)], acquired ability to modify their cell wall structure, which reduces the effectiveness of vancomycin; macrolide resistance; aminoglycoside resistance; quinolone resistance, and biofilm formation (Hiramatsu et al., 2014).Nowadays, recent scientific advances confirmed a novel antibiotic-free means to combat S. aureus antimicrobial resistance.This new therapeutic option is the use of endolysins, enzymes produced by bacteriophages, that can hydrolyze the peptidoglycan layer of bacterial cell walls, leading to bacterial lysis and death.Several studies have demonstrated the efficacy of endolysins in killing multidrug resistant S. aureus such as MRSA and VRSA in vitro and in vivo, including those that are resistant to conventional antibiotics (Schmelcher et al., 2012;Mishra et al., 2021).Endolysins are composed of one N-terminal enzymatically active domain (EAD) and one C-terminal cell wall-binding domain (CBD), connected by a short linker region.Endolysins work by binding to the peptidoglycan layer of the bacterial cell wall and cleaving the bond between the N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) subunits, unique structures not present in mammalian cells, through specific mechanisms includingFrontiers in Cellular and Infection Microbiology frontiersin.org01

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, Multiple, BacterialEndopeptidasesStaphylococcal InfectionsHumansAnti-Bacterial AgentsBacteriophagesMethicillin-Resistant Staphylococcus aureusPhage TherapyStaphylococcus aureus

Stichwörter der Autor:innen

MDR - S. aureuscombating AMRmultidrug resistant Staphylococcus aureusnew therapeutic optionsphage endolysins

Substanzen

Anti-Bacterial AgentsendolysinEndopeptidases

Autor:innen und Institutionen

  • Department of Medical Laboratory Science, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
  • Department of Medical Laboratory Science, College of Health Sciences, Woldia University, Woldia, Ethiopia.
  • Department of Pharmacology, AMR and Nanotherapeutics Laboratory, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, Tamil Nadu, India.

Zitieren

APA

Belete, M. A., Tadesse, S., Tilahun, M., Alemayehu, E., & Saravanan, M. (2024). Phage endolysins as new therapeutic options for multidrug resistant Staphylococcus aureus: an emerging antibiotic-free way to combat drug resistant infections. Frontiers in Cellular and Infection Microbiology, 14. https://doi.org/10.3389/fcimb.2024.1397935

Vancouver

Belete MA, Tadesse S, Tilahun M, Alemayehu E, Saravanan M. Phage endolysins as new therapeutic options for multidrug resistant Staphylococcus aureus: an emerging antibiotic-free way to combat drug resistant infections. Frontiers in Cellular and Infection Microbiology. 2024;14. doi:10.3389/fcimb.2024.1397935

BibTeX
@article{Belete2024,
  author = {Belete, Melaku Ashagrie and Tadesse, Selamyhun and Tilahun, Mihret and Alemayehu, Ermiyas and Saravanan, Muthupandian},
  title = {Phage endolysins as new therapeutic options for multidrug resistant Staphylococcus aureus: an emerging antibiotic-free way to combat drug resistant infections},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fcimb.2024.1397935}
}
Kostenlos starten →